$8.050
0.000 (0.00%)At close
VIGL News
VIGL Events
Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart
Vigil Neuroscience announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. "We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline," said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease."
Vigil Neuroscience sees cash runway into 2026
Cash, cash equivalents, and marketable securities were $87.1 million as of March 31, 2025, compared to $97.8 million as of December 31, 2024. The Company expects its cash, cash equivalents and marketable securities will fund its operational plans into 2026.
Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year
"During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "For VG-3927, we reported positive Phase 1 data in January 2025 that support the planned initiation of a Phase 2 trial in Alzheimer's disease patients in Q3. We also presented these findings at the AD/PD scientific conference, further highlighting VG-3927's potential as a differentiated next-generation therapeutic candidate for the treatment of AD. Additionally, we have remained focused on advancing iluzanebart through the final stages of the Phase 2 trial in ALSP, with the full data readout on track for Q2. With continued momentum across both programs, we are well-positioned to deliver on key clinical milestones in 2025 that will support our commitment and mission to bring these potentially transformative therapies to patients and their families."
Vigil presents data on oral small molecule program including VG-3927
Vigil Neuroscience presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases being held April 1 - April 5 in Vienna, Austria. Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer's Disease / Key highlights from this presentation demonstrated: VG-3927 is an orally bioavailable small molecule TREM2 agonist that has high specificity for membrane-bound TREM2 versus soluble TREM2, which leads to increased access to the therapeutic site of action. VG-3927 shows a unique, synergistic activation of TREM2 with endogenous TREM2 ligands such as aggregated amyloid-beta (Abeta) that is expected to drive enhanced potency and specificity in regions of pathology. New data in 5xFAD plaque-burdened mice illustrate that small molecule TREM2 agonism enhances microglial uptake of both Abeta and Tau supporting the broad efficacy potential of the TREM2 agonist approach to go beyond targeting a single driver of AD pathology. Oral presentation by Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer: Phase 1 Study of VG-3927, A Novel Oral TREM2 Agonist. Key highlights from the presentation: The Phase 1 trial of 115 participants provided a comprehensive and robust dataset evaluating healthy volunteers, elderly participants and a cohort of AD patients. VG-3927 demonstrated a favorable safety and tolerability profile across all cohorts with no serious adverse events. All treatment-related adverse events were mild or moderate and self-resolving. VG-3927 showed a predictable and dose-dependent pharmacokinetic profile that supports once-daily dosing. These data demonstrated that VG-3927 has high CNS penetrance with an estimated cerebral spinal fluid to unbound plasma ratio of 0.91. PK and sTREM2 reduction observed in the single dose AD cohort was consistent with healthy volunteers and the reduction in sTREM2 was similar across evaluated TREM2 and ApoE genetic variants supporting development in AD across genotypes. PK and sTREM2 reduction observed in the multiple ascending dose elderly cohort was consistent with healthy volunteers. At the 25 mg dose, VG-3927 achieved the maximum sTREM2 reduction in the CSF of approximately 50%. PK/PD data support the selection of a 25 mg once-daily oral dose for the Phase 2 trial in AD patients.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.